Brad Margus has recently founded Exigence Neurosciences, a new drug discovery company. In 2013, Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic and clinical data.
From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Margus raised $8 million from investors, discovered new compounds for brain diseases, and sold the company to a global pharmaceutical company for $140 million.
From 2000 to 2007, Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation. Concurrent with his business career, for the last 20 years, Margus has passionately worked as founder and volunteer President of the A-T Children’s Project, a non-profit that orchestrates research on a rare, brutal, genetic disease — ataxia telangiectasia or “A-T” — that two of his sons have. A-T causes neurodegeneration, cancer and immune system problems.
Margus also currently serves on the Boards of Second Genome, a microbiome company; Arvinas, a protein degradation and cancer company; and Cellular Research, a molecular biology tool company. In addition, Margus co-chairs the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) External Oversight Board at the National Institutes of Health.